Harrow, Inc. Announces Director Departure, New CMO, Fiscal Year Change
Ticker: HROW · Form: 8-K · Filed: Aug 25, 2025 · CIK: 1360214
| Field | Detail |
|---|---|
| Company | Harrow, INC. (HROW) |
| Form Type | 8-K |
| Filed Date | Aug 25, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $400,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, corporate-governance, fiscal-year-change
Related Tickers: HROW
TL;DR
Harrow Inc. swapped a director for a new CMO and changed its fiscal year end to June 30.
AI Summary
On August 21, 2025, Harrow, Inc. filed an 8-K report detailing several key events. The company announced the departure of Director Mark L. Baum and the appointment of Dr. Michael J. Ryan as Chief Medical Officer. Additionally, Harrow, Inc. amended its Articles of Incorporation to change its fiscal year end from December 31 to June 30, effective immediately.
Why It Matters
These changes indicate potential shifts in leadership and financial reporting structure for Harrow, Inc., which could impact investor analysis and strategic direction.
Risk Assessment
Risk Level: medium — Changes in key personnel and fiscal year adjustments can introduce uncertainty and require investors to re-evaluate the company's financial reporting and leadership stability.
Key Players & Entities
- Harrow, Inc. (company) — Filer
- Mark L. Baum (person) — Departing Director
- Michael J. Ryan (person) — Appointed Chief Medical Officer
- August 21, 2025 (date) — Report Date
- June 30 (date) — New Fiscal Year End
- December 31 (date) — Previous Fiscal Year End
FAQ
Who has departed from Harrow, Inc.'s board of directors?
Mark L. Baum has departed from Harrow, Inc.'s board of directors as of August 21, 2025.
Who has been appointed as the new Chief Medical Officer?
Dr. Michael J. Ryan has been appointed as the new Chief Medical Officer of Harrow, Inc.
What change has been made to Harrow, Inc.'s fiscal year?
Harrow, Inc. has amended its Articles of Incorporation to change its fiscal year end from December 31 to June 30.
When was the fiscal year change effective?
The change in fiscal year end to June 30 is effective immediately as of the filing date of August 25, 2025.
What other item information is listed in this 8-K filing?
This 8-K filing also includes information regarding the election of directors, appointment of certain officers, compensatory arrangements of certain officers, and financial statements and exhibits.
Filing Stats: 1,056 words · 4 min read · ~4 pages · Grade level 11.1 · Accepted 2025-08-25 07:07:42
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share HROW The Nasdaq
- $400,000 — ll receive (i) an annual base salary of $400,000, (ii) a target cash bonus award opportu
Filing Documents
- form8-k.htm (8-K) — 53KB
- ex3-1.htm (EX-3.1) — 204KB
- 0001641172-25-025336.txt ( ) — 506KB
- hrow-20250821.xsd (EX-101.SCH) — 4KB
- hrow-20250821_def.xml (EX-101.DEF) — 26KB
- hrow-20250821_lab.xml (EX-101.LAB) — 36KB
- hrow-20250821_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 7KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HARROW, INC. Dated: August 25, 2025 By: /s/ Andrew R. Boll Name: Andrew R. Boll Title: President and Chief Financial Officer